U.S. health authorities came close to simply warning about a blood-clotting risk from Johnson & Johnson’s Covid-19 vaccine, but they decided to recommend pausing use out of concern doctors would improperly treat the condition, people familiar with the matter said.
Over the previous four weeks, U.S. health officials had become alarmed about similar blood-clotting conditions in Europe involving a Covid-19 vaccine from AstraZeneca PLC, the people said. The officials dug into a U.S. vaccine safety database and identified the cases of great concern, but they debated what action to take.
By the night of April 12, the officials resolved that urgent action was needed, the people said. Four of six women in the U.S. who developed the clots days after vaccination had initially been given blood thinner heparin, according to the federal Centers for Disease Control and Prevention. Its use could have worsened the patients’ condition, the people said.
Author(s): Thomas M. Burton and Betsy McKay
Publication Date: 18 April 2021
Publication Site: Wall Street Journal